 The Data and Safety Monitoring Committee DSMC has completed a pre-specified interim analysis for ARCA biopharma Incs NASDAQ: ABIO ASPEN-COVID-19 Phase 2b trial evaluating rNAPc2, a small recombinant protein for COVID-19. Based on the review of approximately 75 of the projected final efficacy and safety data, DSMC recommended completing the trial with no modifications to the trial design. 